Table 3 Entero-pancreatic dynamics following a mixed meal.

From: Glycemic variability and entero-pancreatic hormones signatures after different bariatric surgery procedures: a cross-sectional study

 

C-RYGB

M-RYGB

SADI-S

BPD-DS

Glucose

Fasted (mmol/L)

4.5 [4.2–4.8]

4.6 [4.3–4.8]

4.4 [4.0–4.7]

4.4 [4.1–4.7]

Peak (mmol/L)

8.8 (8.5–9.4)

8.8 (7.2–9.2)

7.0 (6.6–8.2)

5.4 (5.2–6.7)

Nadir (mmol/L)

2.8 [2.3–3.4]

3.4 [2.9–3.8]

3.7 [3.1–4.2]

3.0 [2.5–3.6]

MMGR

3.3 [2.6–3.9]

2.5 [2.1–3.0]

2.0 [1.8–2.2]

2.0 [1.6–2.3]

tAUC (0’–30’) (mmol/L × min)

208 [194–222]

190 [177–204]

168 [157–180]

149 [136–162]

tAUC (0’–120’) (mmol/L × min)

637 [587–687]

683 [596–770]

620 [536–705]

526 [441–611]

TAA

Fasted (μmol/L)

1627 [1389–1864]

1336 [994–1678]

1161 [867–1455]

1042 [884–1201]

tAUC (0’–45’) (mmol/L × min)

114.2 [101.2–127.2]

99.0 [75.7–122.3]

93.4 [72.0–114.4]

59.2 [43.4–75.0]

tAUC (0’–120’) (mmol/L × min)

268.4 (261.5–294.8)

262.8 (234.9–295.4)

245.4 (231.9–269.6)

123.6 (105.5–204.5)

Heart rate

Fasted (bpm)

62 (55–71)

60 (58–76)

64 (57–73)

67 (55–80)

tAUC (0’–30’) (bpm × min)

2436 (2247–2715)

2119 (2006–2490)

2051 (1721–2085)

2040 (1767–2399)

tAUC (0’–120’)(bpm × min)

9306 (8795–10204)

8486 (7886–10035)

8419 (7785–9053)

8250 (7616–9419)

Insulin

Fasted (pmol/L)

45.7 (41.9–54.5)

33.8 (26.7–47.3)

30.8 (19.0–40.4)

35.2 (21.0–45.3)

tAUC (0’–45’) (nmol/L × min)

64.6 (34.7–78.7)

26.2 (12.3–29.3)

22.5 (15.8–35.4)

17.3 (10.8–29.2)

tAUC (0’–120’) (nmol/L × min)

94.8 [65.2–124.3]

54.3 [37.9–70.7]

44.7 [31.7–57.8]

37.5 [25.5–49.5]

C-peptide

Fasted (pmol/L)

578.1 (499.1–615.8)

478.3 (373.9–580.6)

399.0 (333.8–532.1)

330.3 (309.3–495.9)

tAUC (0’–45’) (nmol/L × min)

154.3 (99.5–172.3)

84.9 (61.2–91.1)

66.5 (60.1–90.4)

59.9 (44.4–70.8)

tAUC (0’–120’) (nmol/L × min)

322.6 (241.2–380.5)

227.5 (186.3–297.6)

176.9 (160.8–242.2)

167.0 (145.4–194.3)

Glucagon

tAUC (0’–30’) (nmol/L × min)

322.7 [257.3–388.2]

343.9 [198.8–489.1]

414.9 [285.4–544.4]

332.9 [271.8–393.9]

tAUC (0’–120’) (nmol/L × min)

1428 [1144–1713]

1746 [1193–2298]

1650 [1194–2106]

1285 [901.6–1668]

Total GIP

tAUC (0’–30’) (pmol/L × min)

1632 (1536–2340)

922 (742–1103)

540 (257–938)

390 (236–841)

tAUC (0’–120’) (pmol/L × min)

5018 (4281–6925)

3420 (2498–3668)

1628 (864–4389)

1418 (1181–3389)

Total GLP-1

tAUC (0’–30’) (pmol/L × min)

2869 (2239–3358)

2633 (2048–2970)

1828 (1562–3048)

1527 (1267–2676)

tAUC (0’–120’) (pmol/L x min)

7898 (6205–10142)

13388 (7808–14670)

6612 (5948–9485)

5993 (4576–9117)

Neurotensin

tAUC (0’–30’) (pmol/L × min)

3004 (2014–5546)

3900 (2018–5153)

2012 (1159–4013)

2455 (2150–3181)

tAUC (0’–120’) (pmol/L × min)

12481 (7707–16622)

17025 (10553–21638)

9360 (6176–15630)

14010 (12110–15488)

  1. Entero-pancreatic hormone profile during the meal test distributed per study group (classic gastric bypass [C-RYGB, n = 8], metabolic gastric bypass [M-RYGB, n = 7], single anastomosis duodenal-ileal bypass with gastric sleeve [SADI-S, n = 8] and biliopancreatic diversion with gastric sleeve [BPD-DS, n = 7]. Data are presented as mean [95% confidence interval of the mean] or median (interquartile range).
  2. tAUC total area under the curve, TAA total amino acids, GIP glucose-dependent insulinotropic polypeptide, GLP-1 glucagon-like peptide-1.